Reactive oxygen species-based nanomaterials for the treatment of myocardial ischemia reperfusion injuries

Tianjiao Zhao; Wei Wu; Lihua Sui; Qiong Huang; Yayun Nan; Jianhua Liu; Kelong Ai

Bioactive Materials (Jan 2022)

Reactive oxygen species-based nanomaterials for the treatment of myocardial ischemia reperfusion injuries

Tianjiao Zhao,
Wei Wu,
Lihua Sui,
Qiong Huang,
Yayun Nan,
Jianhua Liu,
Kelong Ai

Affiliations

Tianjiao Zhao: Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410087, China; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410008, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410087, China
Wei Wu: Department of Geriatric Surgery, Xiangya Hospital, Central South University, Changsha, 410087, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410087, China
Lihua Sui: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410008, China; Hunan Provincial Key Laboratory of Cardiovascular Research, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410008, China
Qiong Huang: Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410087, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410087, China; Corresponding author. Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410087, China.
Yayun Nan: Geriatric Medical Center, Ningxia People's Hospital, Yinchuan, 750003, China
Jianhua Liu: Department of Radiology, The Second Hospital of Jilin University, Changchun, 130041, China
Kelong Ai: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410008, China; Hunan Provincial Key Laboratory of Cardiovascular Research, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410008, China; Corresponding author. Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China.

Journal volume & issue: Vol. 7
pp. 47 – 72

Abstract

Read online

Interventional coronary reperfusion strategies are widely adopted to treat acute myocardial infarction, but morbidity and mortality of acute myocardial infarction are still high. Reperfusion injuries are inevitable due to the generation of reactive oxygen species (ROS) and apoptosis of cardiac muscle cells. However, many antioxidant and anti-inflammatory drugs are largely limited by pharmacokinetics and route of administration, such as short half-life, low stability, low bioavailability, and side effects for treatment myocardial ischemia reperfusion injury. Therefore, it is necessary to develop effective drugs and technologies to address this issue. Fortunately, nanotherapies have demonstrated great opportunities for treating myocardial ischemia reperfusion injury. Compared with traditional drugs, nanodrugs can effectively increase the therapeutic effect and reduces side effects by improving pharmacokinetic and pharmacodynamic properties due to nanodrugs’ size, shape, and material characteristics. In this review, the biology of ROS and molecular mechanisms of myocardial ischemia reperfusion injury are discussed. Furthermore, we summarized the applications of ROS-based nanoparticles, highlighting the latest achievements of nanotechnology researches for the treatment of myocardial ischemia reperfusion injury.

Published in Bioactive Materials

ISSN: 2452-199X (Online)
Publisher: KeAi Communications Co., Ltd.
Country of publisher: China
LCC subjects: Technology: Electrical engineering. Electronics. Nuclear engineering: Materials of engineering and construction. Mechanics of materials; Science: Biology (General)
Website: https://www.keaipublishing.com/en/journals/bioactive-materials/

About the journal

Abstract

Keywords